Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

investments of dan watson as of 6/19/2019

image145

Seeking Biotech Alpha June 2019 Insight

ELEVATE UC 52

image146

 Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Mon June 17, 2019 8:30 AM|PR Newswire|About: ARNA

  • - ELEVATE UC clinical trial sites continue to initiate

PR Newswire

SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) (Nasdaq: ARNA)

ETRASIMOD

LINZESS® (linaclotide)

image147

 Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Tue June 18, 2019 4:05 PM|Business Wire|About: AGN, IRWD 

LINZESS® (linaclotide) is a prescription medication used in adults to treat irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC). "Idiopathic" means the cause of the constipation is unknown

KANJINTI™ (trastuzumab-anns)

image148

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

  • Thu June 13, 2019 7:13 PM|PR Newswire|About: AGN, AMGN
  • Third FDA Approval From Amgen's Biosimilars Portfolio

PR Newswire

THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN)

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN

BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

image149

 BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

Tue June 18, 2019 7:00 AM|GlobeNewswire|About: BGNE

CAMBRIDGE, Mass. and BEIJING, China and STAMFORD, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

SpringWorks Therapeutics is advancing a pipeline of standalone and combination therapies with an initial focus on severe rare diseases and oncology. We are working with urgency on behalf of the underserved patients living with these devastating illnesses.

Gilead and Nurix

image150

 Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

Wed June 19, 2019 8:30 AM|GlobeNewswire|About: GILDGlobeNewswire

FOSTER CITY, Calif. and SAN FRANCISCO, June 19, 2019 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc

Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels.

Amgen And The Institute For Protein Design (IPD) At University Of Washington

image151

 Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

Wed June 19, 2019 4:00 PM|PR Newswire|About: AMGNPR Newswire

THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD)


 https://www.prnewswire.com/news-releases/amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce-unique-strategic-research-partnership-300871544.html 

The goal of the Institute for Protein Design is to develop and apply methods for designing a whole new world of synthetic proteins to address these challenges.

Seeking Biotech Alpha June 2019 Insight

Resiniferatoxin (RTX)

image152

Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial

Wed June 19, 2019 7:00 AM|GlobeNewswire|About: SRNE 

RTX (non-opioid control of terminal cancer pain with a single injection)

REGN1979 is an investigational bispecific monoclonal antibody

image153

 Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

Fri June 14, 2019 7:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y., June 14, 2019 /PRNewswire/ 

une 14, 2019 at 7:00 AM EDT Back REGENERON CD20XCD3 BISPECIFIC REGN1979 SHOWS POSITIVE RESULTS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, INCLUDING IN CAR-T FAILURES TARRYTOWN, N.Y., June 14, 2019 /PRNewswire/ --

guselkumab (Tremfya(R))

image154

 MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis

Fri June 14, 2019 8:20 AM|Accesswire|About: JNJ, MOR, MPSYY

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 14, 2019 / MorphoSys AG (MPSYF) (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) 

TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light or UV light).

ULTRA® Multifocal

image155

 Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

Wed June 19, 2019 7:00 AM|PR Newswire|About: BHC

New Lens is the Most Advanced Soft Contact Lens Design in Bausch + Lomb History

Only Multifocal Toric Lens that Offers Eye Care Professionals a Convenient Same-Day Fit to Address Patients with Astigmatism and Presbyopia

BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (BHC)

PRESBYOPIC CONTACT LENSES

Taltz® (ixekizumab)

image157

Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Fri June 14, 2019 3:24 PM|Canada Newswire|About: LLY

TORONTO, June 14, 2019 /CNW/ - Eli Lilly and Company (LLY)

Taltz is a prescription medicine also known as ixekizumab. Taltz is an injectable medicine used to treat adults: With moderate to severe plaque psoriasis. It is for people who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). With active psoriatic arthritis.

Seeking Biotech Alpha June 2019 Insight

vosoritide

image159

BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia

Tue June 18, 2019 8:31 AM|PR Newswire|About: BMRNPR Newswire

SAN RAFAEL, Calif., June 18, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN)

Vosoritide (BMN 111) for Achondroplasia Vosoritide is designed for the treatment of achondroplasia, the most common form of dwarfism.

tislelizumab, an investigational anti-PD-1 antibody,

image161

BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)

Fri June 14, 2019 2:30 AM|GlobeNewswire|About: BGNEGlobeNewswire

CAMBRIDGE, Mass. and BEIJING, China, June 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

Tislelizumab

Seeking Biotech Alpha June 2019 Insight

ORENCIA® (abatacept)

image165

 New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients

Thu June 13, 2019 4:30 PM|Business Wire|About: BMY 

ORENCIA® (abatacept) ORENCIA is used to reduce signs and symptoms of moderate to severe Rheumatoid Arthritis (RA) in adults 18 years and older. Taking ORENCIA may prevent further damage to your bones and joints, and may help your ability to perform daily activities. ORENCIA may help those who are not getting the results they need with other medicines for RA.

CALQUENCE® (acalabrutinib)

image166

CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory  

Chronic Lymphocytic Leukemia

Sat June 15, 2019 7:00 AM|Business Wire|About: AZN

An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine

WILMINGTON, Del.--(BUSINESS WIRE)--

CALQUENCE is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.

ULTOMIRIS® (ravulizumab)

image168

 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tue June 18, 2019 6:30 AM|Business Wire|About: ALXN 

ULTOMIRIS is the first and only long-acting medication approved by the FDA, dosed every 8 weeks after the loading dose, to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).

KEYTRUDA® (pembrolizumab)

image169

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

Tue June 18, 2019 6:45 AM|Business Wire|About: MRK

Marks First Approval for KEYTRUDA in SCLC

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended.

Seeking Biotech Alpha June 2019 Insight

INGREZZA® (valbenazine)

image170

 Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders

Tue June 11, 2019 4:01 PM|PR Newswire|About: NBIX

- Pooled Analyses of Two Pivotal Studies Showed Opicapone Reduced OFF Time and Was Generally Well Tolerated in More than 500 Patients with Parkinson's Disease and Motor Fluctuations

PR Newswire

SAN DIEGO, June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX)


 https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-and-opicapone-at-the-2019-world-congress-on-parkinsons-disease-and-related-disorders-300865804.html 

INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

Rituxan® (rituximab), in combination with glucocorticoids (GCC)

image171

FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders

Wed June 12, 2019 1:00 AM|Business Wire|About: RHHBY

  • There are currently no FDA approved treatments for children living with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
  • The PePRS study is the first global trial of Rituxan in pediatric patients with GPA or MPA
  • Rituxan in combination with glucocorticoids is the only FDA-approved therapy for adults with these two rare forms of vasculitis
  • If approved, this would be the first pediatric indication for Rituxan

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

Rituxan is a prescription medicine used to treat adults with: Non-Hodgkin’s Lymphoma (NHL): alone or with other chemotherapy medicines. Chronic Lymphocytic Leukemia (CLL): with the chemotherapy medicines fludarabine and cyclophosphamide. Rheumatoid arthritis (RA): with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA in adults, after treatment with at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well enough. Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA): with glucocorticoids. Pemphigus Vulgaris (PV): to treat moderate to severe PV.

Zanubrutinib

image172

BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)

Wed June 12, 2019 4:00 AM|GlobeNewswire|About: BGNEGlobeNewswire

CAMBRIDGE, Mass. and BEIJING, China, June 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

Zanubrutinib (BGB-3111) — an investigational small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies.

ALKS 4230 in treating patients with renal cell carcinoma or melanoma

image174

 

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

Wed June 12, 2019 7:00 AM|PR Newswire|About: ALKS 


 PR Newswire

DUBLIN, June 12, 2019 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS) 


 https://www.prnewswire.com/news-releases/alkermes-advances-alks-4230-into-monotherapy-expansion-phase-of-artistry-1-in-patients-with-renal-cell-carcinoma-or-melanoma-300866051.html 


 http://www.alkermes.com/ 

A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

oral semaglutide

image175

 Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

SAN FRANCISCO, June 11, 2019 /PRNewswire/

Ozempic® (semaglutide) injection 0.5 mg or 1 mg is an injectable prescription medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar.

Seeking Biotech Alpha June 2019 Insight

Array BioPharma (ARRY)

image176

 Array BioPharma (ARRY) Investor Presentation - Slideshow

Jun. 11, 2019 3:49 PM ET | About: Array BioPharma Inc. (ARRY) 

OUR PIPELINE

SKYRIZI™ (risankizumab)

image177

 June 11, 2019

New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance


 NORTH CHICAGO, Ill., June 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), 

SKYRIZITM (risankizumab-rzaa) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

INVOKANA® (canagliflozin)

image178

 INVOKANA® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis 

 SAN FRANCISCO, June 11, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson 

NVOKANA® is a prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who have known heart disease

PD-L1 IHC 22C3 pharmDx assay

image179

 

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

Tue June 11, 2019 7:56 AM|Business Wire|About: A

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab)

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A


 https://www.businesswire.com/news/home/20190611005542/en/ 

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) June 11, 2019 07:56 AM Eastern Daylight Time SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A)

Bravos™ afterloader system for High Dose Rate (HDR) brachytherapy treatments

image180

Varian to Demonstrate New Bravos Afterloader System at ABS 2019

Tue June 11, 2019 8:15 AM|PR Newswire|About: VAR

PALO ALTO, Calif., June 11, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR

Varian to Demonstrate New Bravos Afterloader System at ABS 2019 June 11, 2019 PALO ALTO, Calif., June 11, 2019 /PRNewswire/ -- Varian (NYSE: VAR

Seeking Biotech Alpha June 2019 Insight

MAVYRET™ (glecaprevir and pibrentasvir)

image182

AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

Mon June 10, 2019 8:00 AM|Canada Newswire|About: ABBV

  • MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1
  • MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease (CKD).

MONTREAL, June 10, 2019 /CNW/ - AbbVie (ABBV)


 http://www.abbvie.ca/ 

MAVYRET™ (glecaprevir and pibrentasvir) tablets are a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.

KEYTRUDA® (pembrolizumab)

FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)

Tue June 11, 2019 6:45 AM|Business Wire|About: MRK

KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS ≥1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)


 https://www.businesswire.com/news/home/20190611005275/en/ 

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS ≥1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression

Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab)

image184

FDA Grants Genentech’s Polivy Accelerated Approval for People with Previously Treated Aggressive Lymphoma

Mon June 10, 2019 12:36 PM|Business Wire|About: RHHBY

– New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen –

– First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells –

– Ninth indication with Breakthrough Therapy Designation in Genentech’s hematology portfolio to receive FDA approval –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)


 https://www.businesswire.com/news/home/20190610005588/en/ 

POLIVY is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have had at least 2 prior therapies.

XERAVA™ (eravacycline)

image185

Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting

Mon June 10, 2019 7:00 AM|Business Wire|About: TTPH

-Study Examines Microbiology and Hospitalization Outcomes Among Complicated Intra-Abdominal Infection Patients-

-Data Underscore XERAVA’s Role as an Empiric Treatment Option for Patients With Complicated Intra-Abdominal Infections-

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (TTPH) (NASDAQ:TTPH)


 https://www.businesswire.com/news/home/20190610005030/en/ 

XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.

Vicinium®

image186

 Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®

Mon June 10, 2019 7:00 AM|Business Wire|About: SESN

FDA Recommends Accelerated Approval Pathway

FDA Indicated No Additional Clinical Trials Necessary for BLA Submission

Company Expects to Initiate Submission of the BLA in 4Q 2019 Under Rolling Review

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sesen Bio (SESN) (Nasdaq:SESN)


 https://www.businesswire.com/news/home/20190610005190/en/ 

Vicinium is being evaluated in the Phase 3 VISTA trial for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG), which is the current standard of care for NMIBC.

Seeking Biotech Alpha June 2019 Insight

Tradjenta® (linagliptin)

image188

 

Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®

Mon June 10, 2019 9:30 PM|PR Newswire|About: LL 


 

  • Adults with diabetes treated with Tradjenta experienced fewer events of hypoglycemia and a modest weight reduction compared with glimepiride
  • - Detailed results from CAROLINA were presented at the American Diabetes Association's 79th Scientific Sessions

PR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, June 10, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY


 https://www.tradjenta.com/ 


 https://www.prnewswire.com/news-releases/detailed-findings-from-carolina-outcome-trial-support-long-term-cardiovascular-safety-profile-of-tradjenta-300864614.html 

TRADJENTA is a prescription medicine that is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

Taltz® (ixekizumab)

image189

 

Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

Tue June 11, 2019 3:00 AM|PR Newswire|About: LLY

INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY


 https://www.taltz.com/ 

INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

Gazyva (Obinutuzumab)

image190

Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study

Tue June 11, 2019 1:00 AM|Business Wire|About: RHHBY

  • NOBILITY showed that Gazyva helped more patients achieve a complete renal response when added to standard of care
  • The Phase II study met both primary and key secondary endpoints
  • There are currently no FDA-approved therapies for lupus nephritis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)


 https://www.businesswire.com/news/home/20190610005836/en/ 

GAZYVA® (obinutuzumab) is a prescription medicine used in combination with chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III or IV follicular lymphoma (FL) in adults who have not had previous FL treatment. GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment. GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment.

FARXIGA (dapagliflozin)

image192

FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

Mon June 10, 2019 8:00 AM|Business Wire|About: AZN

FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58

WILMINGTON, Del.--(BUSINESS WIRE)


 https://www.businesswire.com/news/home/20190610005198/en/ 

FARXIGA is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

BIOTECH-WARS™ & BIOTECH$TORM (DANWATSON BLOGS)

BIOTECH-WARS™

image260

 Jun. 8, 2019 5:21 PM ET|About: Amgen Inc. (AMGN), AZN, BMY, CELG, LLY, MRK, PFE

Summary

politicos started the BIOTECH-WARS™ and they are continuing the war.

the BIOTECH-WAR$ led to the vilification of the biotech sector.

the Biotech industry severely miscalculated and underestimated the situation they find themselves in.

BIOTECH$TORM™ II

image261

 Jun. 5, 2019 4:18 PM ET|About: AbbVie Inc. (ABBV), AMGN, BMRN, CELG, JNJ, LLY, MRK, NVS, PFE, RHHBY

Summary

The perfect BIOTECH$TORM is not over, perhaps it is only in the early stages.

In NJ more taxes coming, more pain, more debt, unfunded liabilities, and in my view a rapid exit of many high-income people from my home state of New Jersey.

Nevertheless, meanwhile and more importantly Biotech Companies continue to make significant product and financial progress irrespective of the negative political environment that only seems to be getting worse.

 

BIOTECH$TORM™

image262

 Jun. 3, 2019 12:30 PM ET|About: Amgen Inc. (AMGN), AZN, BMY, CELG, GILD, MRK, NVS, RHHBY, SGEN

Summary

The Perfect BIOTECH$TORM is occurring right now, June 2019.

Trade Wars, Legal Battles, Political Battles, all impact to create the Perfect BIOTECHSTORM.

Nevertheless Biotech companies continue to develop wonderful new products every day.

BIOTECH WAR$ 4

image263

 May 24, 2019 11:56 AM ET|About: Celgene Corporation (CELG), JNJ, LLY, MRK, NVS, Includes: ABBV, ARRY, MDT, PFE

Summary

the BIOTECH WAR$ have expanded to include a new and unexpected target, “wealthy people”.

the victorious party wants to remove all undesirable citizens/unlikely supporters from the state in which they live. Acrimony against biotech companies and now wealthy citizens is where we are at.

Biotech companies are an insufficient sector to the politico’s, and a more expansive “Bad Guy Group” is now needed – i.e., wealthy people, especially if you live in NJ

BIOTECH WAR$™ III

image264

 May 9, 2019 8:52 AM ET|About: Johnson & Johnson (JNJ), MRK

Summary

the BIOTECH WAR$ may represent a deeper battle going on between the “Socialist” political movement and our current “Capitalistic” economy.

Achieving political power supersedes common sense and support for the biotech business sector becomes non-existent as the sector is politically vilified.

Positive biotech product news seems to have little effect towards improving market valuations.

BIOTECH WAR$ II™

image265

 Apr. 30, 2019 5:44 PM ET|About: Amgen Inc. (AMGN), JNJ, MRK, Includes: BMY, CELG, NVO, NVS, PFE, RHHBY

Summary

The “Medicare for all” and the “drug pricing” messaging is working for all those who seek political gain.

Biotech, Medtech and the entire Healthcare sector are losing the battles, and the war as investors flee for less politically targeted sectors.

NJ residents see the "P/C", "Middle Class Only"/ Socialism wave coming.

I may need to stop being so publicly supportive of Biotech companies.

 

BIOTECH VORTEX™ & BIOTECH WARS (Danwatson blogs)

Biotech Vortex™

 Feb. 20, 2019 11:04 PM ET|Includes: AbbVie Inc. (ABBV), ABT, ALKS, AMGN, CELG, CERC, CLVS, JNJ, LLY, MDT, MRK, NVO, PFE

Summary

A BIOTECH VORTEX™ is occurring across the entire healthcare sector as companies are now Seeking Biotech Partnerships to gain momentum.

Biotech & Biotech Partnerships.

Biotech & Medtech Partnerships.

Biotech & Medtech & Medical Universities Partnerships.

Biotech & Health Systems Partnerships.

Biotech Vortex™ Feb. 20, 2019 11:04 PM ET|Includes: AbbVie Inc. (ABBV), ABT, ALKS, AMGN, CELG, CERC, CLVS, JNJ, LLY, MDT, MRK, NVO, PFE

Biotech, Biotech, Biotech,

  Mar. 6, 2019 8:12 AM ET|Includes: AbbVie Inc. (ABBV), AMGN, AZN, BMY, CELG, JNJ, LLY, MRK, PFE, SRPT

Summary

Sometimes biotech news is wonderful news.

Sometimes biotech news is the best and most upbeat news I read all day.

Sometimes with great effort and much time and money spent biotech news is remarkable news for many people seeking solutions to specific medical conditions and aliments.

The first 2 months of 2019 have been extremely strong for many of my biotech positions.


Biotech, Biotech, Biotech, Mar. 6, 2019 8:12 AM ET|Includes: AbbVie Inc. (ABBV), AMGN, AZN, BMY, CELG, JNJ, LLY, MRK, PFE, SRPT

IT’S BIOTECH OR NOTHIN’!™


 Feb. 1, 2019 9:27 PM ET|

6 comments |Includes: Abiomed, Inc. (ABMD), BIIB, ILMN, ISRG, MRK, RHHBY, SRPT, VA 


 Almost every piece of company news I was reading was positive and encouraging during the December 2018 time frame. 



IT’S BIOTECH OR NOTHIN’!™ Feb. 1, 2019 9:27 PM ET|6 comments |Includes: ABIOMED, Inc. (ABMD), BIIB, ILMN, ISRG, MRK, RHHBY, SRPT

BIOTECH WARS

 Feb. 12, 2019 4:16 PM ET|2 comments |About: AbbVie Inc. (ABBV), AZN, BMY, JNJ, MRK, PFE, SNY

Summary

Biotech companies are easy targets as they are on TV with their advertised products on a year-round basis and they are successful and profitable.

If an incumbent senator can successfully attack a successful and profitable biotech company, that is in his home state, then so can everyone else.

Should any politician target any biotech company in their home state, then most likely they will win votes and are more likely to win elections.

I think these hearings will eventually benefit biotech companies as insurance companies and PBM's and other "profiteers" in the healthcare pricing matrix are exposed.

As a biotech investor the upcoming/ongoing congressional hearings on drug pricing (2/26/2019) does have me feeling a bit on edge.   


BIOTECH WARS Feb. 12, 2019 4:16 PM ET|2 comments |About: AbbVie Inc. (ABBV), AZN, BMY, JNJ, MRK, PFE, SNY

BioTECH! ZONE

image266

  Apr. 2, 2019 8:20 PM ET|About: AstraZeneca PLC (AZN), BMY, CELG, Includes: AMRN, JNJ, MRK, NVO, NVS, PFE, RHHBY, SNY

Summary

“TINSTAAFL” = “There is no such thing as a free lunch”.

Princeton NJ/Central Jersey – is for me the best example of a successful BioTECH Zone.

Ireland's Life Sciences sector has grown from very humble beginnings in the 1960s to reach global significance. Collaborative clusters in Pharmaceutical, Biotechnology, Medical Devices and Diagnostics have been a key.

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China, that aims to nurture innovation.

Cambridge, Mass, is one of the best examples of a successful BioTECH Zone.

 

 


BioTECH! ZONE Apr. 2, 2019 8:20 PM ET|About: AstraZeneca PLC (AZN), BMY, CELG, Includes: AMRN, JNJ, MRK, NVO, NVS, PFE, RHHBY, SNY Summary “TINSTAAFL” = “There is no such thing as a free lunch”.

Bio-Tech & China, China, China

image267

 Mar. 14, 2018 1:14 PM ET|About: Amgen Inc. (AMGN), AZN, BGNE, CELG, NVS, Includes: ABMD, BMY, LLY, MDT, MRK, NVO

Summary

China Bio-Tech growth is accelerating now.

China needs better healthcare in every province.

China will welcome all bio-technology partnerships.

China is on the verge of major investment changes.

Bio-Tech & China, China, China Mar. 14, 2018 1:14 PM ET|About: Amgen Inc. (AMGN), AZN, BGNE, CELG, NVS, Includes: ABMD, BMY, LLY, MDT, MRK, NVO

My Blog

seeking biotech alpha October 2018 insight

image268

 INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/   

Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
image269

Thu October 4, 2018 6:45 AM|Business Wire|About: MRK

 Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens


Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
image270

 Health Canada OKs AbbVie's elagolix for endometriosis-related pain

Oct. 6, 2018 2:20 PM ET|About: AbbVie Inc. (ABBV)|By: , SA News Editor  

ORILISSA™ (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis.
image271

 Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Wed October 3, 2018 8:30 AM|Business Wire|About: GILD

– Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks –

BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults.
image272

 New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

Sat October 6, 2018 7:30 AM|GlobeNewswire|About: BIIB 

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.
image273

 FDA OKs expanded use for Merck's Gardasil 9 HPV vaccine

Oct. 5, 2018 4:58 PM ET|About: Merck & Co Inc. (MRK)|By: , SA News Editor 

Gardasil 9 HPV vaccine

seeking biotech alpha September 2018 insight

image274

 Thu September 27, 2018 7:52 PM|PR Newswire|About: LLY

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

by Eric Sagonowsky | Sep 27, 2018 8:10pm Lilly’s Emgality nabs third-to-market migraine nod, but aims to be 'treatment of choice' in CGRP
image275

  Thu September 27, 2018 5:41 PM|Business Wire|About: PFE 

 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

U.S. FDA APPROVES VIZIMPRO® (DACOMITINIB)
image276

 by Nick Paul Taylor

Sep 28, 2018 7:33am

 Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests 

Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the treatment of cancer. ​
image277

  Sep. 28, 2018 7:07 AM ET|About: Novo Nordisk A/S (NVO)|By: , SA News Editor 

Novo's once-weekly somapacitan on par with daily Norditropin in mid-stage study

NVO R&D Pipeline
image278

 Thursday, September 20, 2018 - 8:00amEDT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)

 PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR THE PREVENTION OF INVASIVE DISEASE AND PNEUMONIA IN ADULTS AGED 18 YEARS AND OLDER

image279

 SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)  

Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product 


 Novartis (NYSE:NVS) unit Sandoz will commercialize. 

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company focused on developing and commercializing pharmaceutical products in the therapeutic areas of respiratory disease and allergy.

seeking biotech alpha September 2018 insight

image280

 Sep. 18, 2018 8:24 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor   

AstraZeneca's FASENRA shows safety and sustained efficacy in long-term phase III BORA trial in severe eosinophilic asthma

FASENRA IS DESIGNED TO WORK WITH THE BODY TO HELP REMOVE EOSINOPHILS, A KEY CAUSE OF SEVERE ASTHMA.
image281

  September 18, 2018 06:59 AM EDT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY

European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma

EMPLICITI™ (elotuzumab) is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone in people who have received one to three prior treatments for their multiple myeloma.
image282

   Sep. 18, 2018 7:22 AM ET|By: , SA News Editor  

The European Medicines Agency (EMA) accepts for review Bristol-Myers Squibb's (NYSE:BMY) marketing application seeking approval for EMPLICITI (elotuzumab), in combination with Celgene's (NASDAQ:CELG) POMALYST (pomalidomide) and low-dose dexamethasone, for the treatment of adult patients with multiple myeloma (MM) 


POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat people with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment.
image283

 DUBLIN - September 18, 2018 - Medtronic plc (NYSE:MDT)  

(GLOBE NEWSWIRE via COMTEX) --Medtronic Receives FDA Approval for Revised TAVR Labeling and Begins Investigational Study of Low Risk Patients with Bicuspid Valves 

The Evolut™ PRO System combines exceptional valve design and advanced sealing with an excellent safety profile.
image285

 Mon September 24, 2018 9:00 PM|PR Newswire|About: AMGN 

 BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia

BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy.

seeking biotech alpha September 2018 insight

image286

Sep. 14, 2018 4:50 PM ET  | About: Roche Holding Ltd ADR (RHHBY), RHHBF 

Roche Holding's (RHHBY) Virtual Late Stage Pipeline Event 2018 - Slideshow


image287

 Sat September 15, 2018 2:00 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- 

Pfizer Inc. (PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, 

image288

  by john carroll — on September 14, 2018 08:37 AM EDT 

 According to the Albany Times-Union, Regeneron $REGN had already told officials last month that they were expanding their plans for manufacturing, office and lab space in Rensselaer, boosting their initial hiring plans from 1,100 to 1,500 while blueprinting an extra 300,000 square feet of space for the complex. 

image290

  By The ASCO Post
Posted: 9/13/2018 2:20:30 PM
Last Updated: 9/13/2018 5:04:27 PM 

(FDA) today approved moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) 

US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
image291

  TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ 

Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ 

DUPIXENT is the first biologic for adult patients with uncontrolled moderate‑to‑severe atopic dermatitis.1-3

Contact Us

send us a comment

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

seeking biotech alpha

Moorestown, New Jersey, United States

732-232-1334